ISCOM OR ISCOM-MATRIX COMPRISING HYDROPHOBIC RECEPTOR MOLECULES FOR ANTIGENIC SUBSTANCES

Abstract: Lipid-containing particles such as iscoms, iscom-matrix or vesicles such as micelles or liposomes that comprise one or more hydrophobic receptor molecules for targeting and antigenic substances, which receptor molecules have been integrated in the particle and are chosen from lipid-containing receptors or receptors that are hydrophobic, which receptor molecules bind to the antigenic substances.

Description: ISCOM OR ISCOM-MATRIX COMPRISING HYDROPHOBIC RECEPTOR MOLECULES FOR ANTIGENIC SUBSTANCES The invention involves lipid-contaming particles, chosen from lscoms and lscom matrices, which contain one (several) hydrophobic receptor component! s) which bind to antigens from microorganisms such as bacteria, virus, or parts thereof, J e the receptor-binding parts, such as toxins or surface proteins Furthermore, the invention involves procedures for producing such hpid-contaimng particles and the human medical, veterinary medical, or other pharmacological preventive and curative use, such as immunotherapeutic, of these particles The invention involves in particular iscoms and iscom matrices whose surfaces have been prepared with bacterial toxin fragments such as the cholera toxin's B subunit (CTB) The background of the invention Lipid-contarmng structures in the form of micelles, liposomes and other vesicles, iscoms (immune-stimulating complex/particles), iscom matrices, etc have been reported as effective earners of pharmacologically and/or immunologically active substances or molecule complexes See for example WO- A 1 -90/03184 (Morein et al , Chn Immunother Review, 1995, Kersten et al , Iscom— Liposome Review, 1995) In many cases, immunization of laboratory animals with such hpid-contarnrng structures, in which various antigens have been incoφorated. have been shown to give πse to an increased immune response to the referred anUgens as compared to the immune response obtained after immunization using a corresponding antigen in a free form Iscom and iscom matrices are documented as effective earners of antigens and adjuvant molecules to enhance the immunogenicity of small and large molecules (antigens), ; e to make them strongly immunogenic both when they are applied parenterally and locally, (topically) on mucous surfaces The iscom has unique properties being effective after mucosal lntranasal adrrumstration It is well-documented (Morein et al , Chn Immunother 3, 1995, 461-475) that both iscoms with incoφorated antigens (usually protein) and iscoms as earners, for example small antigens such as ohgopeptides or as exemplified by biotin, effectively evoke immune response to these large or small molecules Iscom matnces ( and iscom) have well-documented, built-in, adjuvant activity that potentiates antibody-mediated as well as cell-mediated immune responses to the co- admimstered antigens Iscom evokes cell-mediated immune response under both Class I and Class Ll restriction Cholera is the most senous of all the dianhea diseases and is caused by the Vibno cholera bactena in group 1 These bactena colonize in the small intenstine of human beings and secrete an exotoxin protein known as the cholera toxin This toxin binds to and is absorbed by cells in the mucous membranes and causes an intensive secretion of electrolytes and water from the cells, which leads to the grave cases of dianhea, dehydration, and metabolic acidosis which characterize cholera Similar diseases can be caused by so-called "enterotoxic" (ET) chohbactena, but the symptoms are usually milder Such bactena often cause dianhea in young individuals among humans and practically all kinds of animals, including pigs and cattle These dianheas, which can give πse to great economic losses for the livestock industry, are caused partly by a heat-labile toxin (LT) similar to the cholera toxin (CT) These toxins are so similar that they bind to the same receptors The structures of CT and LT are well defined in regards to structure and function They are ohgomenc proteins consisting of one part that binds to the cholera toxin receptor, namely the B part, which in turn consists of five subunits which each have an approximate mole weight of 1 1.600 and form a pentamer ring The A subunit is a proteolytic split polypeptide with a molecular weight of approximately 28.000, consisting of two disulfid- conjugated fragments The larger A 1 fragment contains toxin-enzyme activity, while the smaller A2 fragment joins the A 1 fragment with the B5 ring CT binds with high affinity to a class of receptors that exist on the surface of the so-called brush-border membranes in the small intestine, as well as to the plasma membrane of most mammalian cells The GM1 ganghosid constitute the receptor for CT (Holmgren et al , Infect Immun 38, 424- 433 ) LT also binds to GM1 CT and LT, respectively, are both important components in the subunit vaccines that are intended to evoke protection against cholera and enterotoxic chohbactena In the case of intestinal infections, it is of special interest to evoke local protection exerted by. among other things, secretory IgA in the intestinal membrane CT and LT are both considered well suited as targeting molecules in adjuvant formulations for vaccines intended for administration in the intestinal and respirator y tracts (Morein. Lovgren and Cox, 1966), with, among other things, having the capacity to induce a secretory IgA response that is an important component in the protection The B subunit of CT and LT have attracted a good deal of interest as earner molecules and even as universal vector systems for oral vaccines (Mucosal Handbook Immunology, eds Ogra, P L , Lamm Me, Mc Ghee Jr , Mestechy J . Strober W . Bienenstock J . 1994) The interest has increased even more because it has been shown that the conjugate between CTB and other antigens not only give nse to immune response in the local intestinal mucosal membranes, but also to a limited extent in other remote mucous membranes, such as the salivary glands, the lungs, the genital tract, and in the blood (Handbook mucosal, 1994) The problem with CTB and LTB is that they have a low (ιnate)-capacιty to potentiate their own strong, protective immune response against the cholera toxin or against LT, or against the antigen that they are modified to be a earner for Thev thus have a low adjuvant activity in relation to the lmmunomodulatory and irnmunopotentiating effect (Morein, Lovgren and Cox, 1966) CTB and LTB are used experimentally as earners of antigen with the pwpose of evoking, through local application (orally), local immune response in the mucous membranes of the digestive tract as well as in other mucous membranes through gut-associated lymphatic traffic (GALT) or through direct application on other mucous membranes such as the respiratory tract CTB and LTB have targeting capacity, which means that they are considered to steer and localize both themselves and the antigens they may carry to the lvmphatic system in the intestinal tract, which means to M-cells in Payer ' s patches, to lamina propna (LP), and to the lymphatic system in the intestines and in other mucous membranes through GALT or through direct application on these mucous membranes, for example in the respiratory tract The following unsolved difficulties exist regarding using CTB and LTB for local immunization 1 CTB and LTB have by their own relatively low immunogenicity and a low lmmunoenhanαng capacity, requiring a need to be potentiated with an adjuvant component to obtain optimal effect In other words, this involves both their own immunogenicity and their lmmunoenhancing effect to the antigens that they may have earned with them Their value as adjuvants is limited to "targeting", while supplementary adjuvant activities in the form of immunomodulatory and lmmunoenhancing capacities are required in order to attam optimal immunogenicity 2 There are limitations to conjugating antigens to CTB and LTB with particularly high physical or economic yield, since only a limited number of amino groups and/or carboxy groups can be activated without senously reducing their values as antigen or as earners in mucous membranes, and target themselves and the accompanying antigens to the lymphatic organs and cells to evoke immune response Even if a suffi ent number of coupling groups are available on a earner molecule, it is well known that it is difficult to attain the desired economic yield from such constructions because of the insuffi ent yield For example, often no more than 15-20% of the available antigens are coupled in reaction to the earner molecule 3 CTB and LTB have a limited space for chemically coupling of larger molecules, because they can block functional epitopes that are necessary for targeting the complexes to the lymphatic organs and cells Summary of the invention It has now been demonstrated that through the use of hpid-containing particles, chosen from iscoms and iscom matnees or micelles or vesicles like liposomes that contain one or more hydrophobic receptor molecules for antigen substances or targeting molecules, a contπbution is made toward a new, general system for binding molecules These receptors can be hpid-containing receptors or receptors that are hydrophobic proteins Through this new, general system, a greater proportion of antigens or other substances are bound to the particle, with a yield that begins to approach 100%, which is economically advantageous, but above all the new system makes it possible, without competition from earlier systems (that do not use the receptor) (EP 0 109 924 Bl, EP 0 180 546 Bl , EP 0 242 380 Bl ), to bind in antigen and targeting molecules or molecule complexes Consequently, the immune response is more eflficientlv induced by the antigens that are bound to the receptor Above all, it becomes possible to bind antigen to the receptor together with the other antigens that are incoφorated without using the receptor With this invention it is easier to bind both targeting molecules which can. for example, penetrate mucous membranes, and passenger antigens which cannot be absorbed by mucous membranes (see the Swedish patent application 9600647-3) A special advantage is that hpid-containing receptors can be used as an integrated pid in the complexes, that is. thev can replace hpids that are used to build up the complex (pat hpid Iscom) Among the receptor-binding components that are compnsed by the invention are. for example, bactenal toxins and their active binding parts in the form of subunits or fragments or vanous modifications or denvatives of them, bactenal fimbnae or other adhesion molecules and their active binding parts and/or denvative structures In many cases these targeting structures are also relevant vaccine antigens, and the presentation of such antigens on the surface of hpid-containing particles, etc., for vaccination use are also part of the invention Iscom contains at least one glycoside, at least one hpid, and at least one kind of antigen substance, particularly proteins and peptides These complexes enhance the immunogenicity of the included antigens and may also contain one or more immunomodulatory (adjuvant- active) substances and are descnbed in EP 0 109 924 B 1 , EP O 242 380 B l and EP O 180 546 Bl Matrix contains at least one glycoside. one adjuvant-active substance and at least one hpid Matrix has an lmmunoenhancing effect on co-admimstered antigemc substances, see EP 0 436 620 B l It has been shown that the hpids in these complexes can be partly replaced by pid- contaimng receptors for antigen substances from microorganisms ,In this way, the amount of antigen that binds to the particle is appreciably increased In those cases where the complexes are iscoms, these iscoms are prepared as descnbed in the European patent EP 0 109 942 Bl Here, virus, mycoplasma, bactena, parasites, animal cells, containing antigens or antigemc determinants, especially proteins or peptides or isolated examples which have hydrophobic or amphiphatic regions, is mixed with one or more solubihzing agents, whereby complexes are formed between antigens or antigemc determinants and solubihzing agents, after which the antigens or determinants are separated from the solubihzing agent in the presence of, or are separated from the solubihzing agent and directly transfeπed to. a glycoside solution, containing cholesterol, phospholipid, and one or more glycosides (Quillaja components) with hydrophobic and hydrophilic domains in a concentration of at least the cntical micelle-binding concentration wherebv a protein complex is formed, which is then isolated and punfied The hpids that are used are in particular those descnbed in the applicant ' s patent EP 0 109 942 Bl , especially on page 3. and in EP 0 436 620 Bl p 7, hnes 7-24 In particular, sterols such are cholesterol and phospho pids such as phosphatidyl- ethanolamine and phosphatidylcho ne are used The hpids can also include lipophilic receptor molecules that bind to cell-binding components, especially antigens Such receptors are glycolipids, for example the cholera toxin's receptor ganghoside GM1 and fucosylated blood group antigen The cell-binding components can then function as transport molecules They are bound to the hpid- containrng receotor by a simple mixing with the complex that contains the receptor Then the iscom or matrix molecule can be mixed with the antigen that binds to the receptor It is possible to proceed from matnx that can be made by solubilizing at least one sterole in a solution agent, adding the glycoside or the sapomnes and the other hpids, after which the solution agent may be removed, if it unacceptable to the final product Matnx is usually transfeπed to a water solution in which its separate parts are not soluble The solubihzing agent can be removed through eg gel filtration, ultra filtration, dialysis, or electrophores The matnx can then be punfied from suφlus of sterole and sapomne eg by ultracentnfugation, through a density gradient or through gel filtration The solubihzing agent can be any of those mentioned in EP 0 436 629 Bl, p 5 row 24-45 The other components and the procedure are also descnbed in this document The glycosides that are used n the procedure can be those descnbed in EP 0 109 942 Bl p 4 last paragraph Especially sapomnes are used, such as tnteφensaponines, especially Quillaja saponins from Quilla a saponana Molina or cell cultures from this tree or subcomponents thereof, especially those descnbed in the applicant's European patent EP 0 436 620 B 1 p 4 rows 19-46 These can be QHA, QHB, QHC. or other compositions of Quillaja saponins The glycosides are adjuvants and structure-building elements in iscom and matnx It is also possible to incoφorate other adjuvants or immunomodulatory components than glycosides in the iscoms or in the matnces as is mentioned in EP 0 436 620 Bl It is also possible to mix the transport molecule and/or the passenger antigen as a separate entity with an iscom particle in which the passenger antigen or the transport (targeting) molecule has been integrated, or with iscom and/or matnx complex on which the passenger antigen or the transport molecule has been coupled, te manv combination are possible By definition, an iscom particle contains antigen and iscom-matnx lack antigen Even other adjuvants or immunomodulatory components can be mixed with the iscom and/or matnx complexes as separate entities, te they do not necessary have to be integrated in the complexes or coupled to these Examples of such adjuvants are provided in Cox et al . CRS, 1992 Usually, MDP, MTP, and avπdin are used It is however advantageous to rncoφorate these adjuvants in iscom and matnx when a lower dosage of adjuvants is required It is also possible to mix both the transport molecule and the passenger antigen with iscom-complex or matnx In these cases, the iscom complex contains another antigen molecule If the transport molecule(s) or passenger antigen(s) lacks hydrophobic or amphiphatic groups, they can be chemically coupled to the iscom particle Examples of such coupling procedure and coupling groups are found in EP 0 242 380 Bl p 9 and in EP 0 436 620 Bl p 6 row 33-p 7 row 6, where the coupling method is also descnbed They can be hpids as in example 7 below The relative amounts of cholesterol, hpids and antigen that can be used can be found in the above-mentioned patents EP 0 109 942 Bl, EP 0 180 564 Bl, EP 0 242 380 Bl and EP 0 436 620 Bl The hpid-containing receptors can also be included in other hpid structures such as liposomes, vesicles, micelles When the receptor is a hydrophobic protein such as a glycoprotein or a fucosylated blood group antigen, it can be integrated in the hpid molecule with a hydrophobic interaction It can also be included in iscom as a protein share Besides the antigen that attach to the receptor, other antigens can be made to attach to the receptor through the substitution of appropnate groups Such appropnate groups, which can be attached to such other antigens, can be parts of the antigen that attach to the receptor These parts can be bound with familiar methods, for example those mentioned in EP 0 436 620 Bl It is also possible through gene-technological manipulation to construct fusion proteins or peptides between an antigen and parts of it and the receptor-binding antigen Other antigens than those that come from cholera and enterotoxic chohbactena can thereby be bound to the GM1 receptor bv substitution with parts of the CTB or LTB Examples of this are given in Biochemia et biophysica Acta 1223 ( 1994) 285-295 "Regeneration of active receptor recognition deomaisn on the B subunit of cholera toxin by formation of hvbnds from chemical! inactivated denvatives". Marc J S De Wolf , Wilfried S H Dienck In this way, antigens that do not normally penetrate a mucous membrane can be passed through the mucous membrane CTB is thereby a useful earner for chemically and genetically produced antigens. Sanchez & Holmgren (Proc Natl Acad Sci USA, 86, 481-485. 1989) and Sanchez, Johansson et al (Res Microbiol 141, 971-979, 1990) With the aid of recombinant DNA techniques, foreign antigens have been bound to the antigen amino or carboxiy ends of the CTB subunit and a gene has been expressed that, via expression systems, has been developed to produce the hybnd protein In the examples descnbed to illustrate the invention, iscom matnx such as hpid-containing particles and the cholera toxin B subunit (CTB) have been used as receptor-specific binding structures and as a relevant vaccine antigen The cholera toxin consists of an A subunit that exerts the toxin activity and the B subunits that attaches the toxin to the plasma membrane on the cell through a glycohpid (GM 1 ) To reduce the toxicity, usually only the B subunit of the cholera toxin (CTB) is used as vaccine antigen to evoke immune response The B subunit is not toxic and evokes a relatively weak immune response as compared to CT after local (mucosal) lntranasal or systemic parenteral immunization, for example subcutaneous or intramuscular immunization, te the B subunit has low adjuvant activity when the activity refers to lmmunomodulating or immuno enhancing activity CTB is also available as a recombinant DNA product (rCTB) (EP 368 819) It is difficult to couple antigen covalently to CTB or LTB with high physical and economic yields, since only a limited number of amino groups and/or carboxy groups can be activated wiώout senously reducing the antigemc activity of CTB and LTB or not to harm their capacitv as earner molecules in the mucous membranes, and to target themselves and accompanying antigens to lymphatic tissues and organs and cells to evoke immune response Even if a sufficient number of groups are available for chemical conjugation of antιgen(s) on a earner molecule, it is well known that it is difficult to receive good and economic yields from such constructions (Lovgren et al . J Immunol Methods K73. 237- 243 ) The utilization of transport proteins in iscoms has several advantages This is especially evident for construction of oral, nasal, or rectal vaccines against infections Such vaccines can contain a earner construction with antigen and adjuvant component(s), supplemented for example with CTB or LTB to localize the construction to lymphatic organs and cells in the intestinal tract and to target immune response to lymphatic tissues in other mucous membranes via GALT, MALT, NALT (Gut, Mucosal and Nasalfaryngial Associated Lymphatic Tissue, respectively), for example after administration in the respiratory tract or by direct local mucosal application The iscom is larger than transport molecules like CTB or LT and therefore there is room to conjugate or in some other way, for example through hydrophobic or electrostatic binding, to rncoφorate chosen passenger antigens and incoφorate chosen adjuvant components In producing matnx, the weight ratio of sterol, second hpid, and glycoside is 0 2- 10 0,2-10 1-100, preferably 1 1 5 If a hpid-contaimng receptor is used, it can replace the other hpιd(s) completely so that the ratio of sterol, hpid-containing receptor, and glycoside will be as above It is also possible to use both the hpid- containing receptor and a second hpid, preferably phosphatidylchohn or phosphatidyl ethanolamin and the receptor so that the ratio becomes sterol second hpid receptor glycoside 0 2-10 0 2-10 0 1 - 1 5-10, preferably 1 1 0 25 5 The amount of receptor molecule depends on the amount of target or antigen molecules one wishes to add on The constitutents can, in principle, be put in any ratio whatsoever It has been proven that the finished product obtains the preferred weight ratio between the included components and that the suφlus does not enter If a large amount of the second hpid, such as phospholipid, is used, the complex becomes fatty and fragile and easily falls apart Too little of the second hpid makes it difficult for complex to be formed, and annulary πng- shaped subunits are formed This can be determined by electron microscopy Whether iscom or matnx has been formed can be confirmed by studying the product by electron rmcroscopv Typical matnx or iscom have a charactensticallv open, sphencal structure containing circular subunits or parts of the sphencal structure, as can be seen in fig 3 in EP 0 109 942 Bl The iscoms have a lower sedimentation constant than the coπesponding micelles and often a higher sedimentation constant than the coπesponding monomenc forms of protein or peptide Matnx and iscom have a sedimentation constant of approximately 20 S The advantage of using hpid-containing receptors for binding target-seeking or vaccine anngens is that it is possible to produce matnx from glycoside, sterol. possibly a second hpid. and a hpid-containing receptor and then simply mix the ready matnx with the transport (targeting) molecule The procedure is cheaper and simpler than if one were to make ready-made iscom containing the ingredients above plus a transport antigen, or if one were to join the antigen to ready-made matnx using chemical conj ugation methods When the antigen is integrated into iscom or is coupled chemically to matnx, amino groups or carboxyl groups, which can constitute antigenic determinants, are modified The antigemc determinants are denatured when the antigen is activated for integration in iscom or when it is coupled chemically to matnx or iscom (when two antigens are used, iscom already contains at least one antigen) This means that the active antigen amount is considerably reduced Moreover, the recovery is low compared to when the antigen is allowed to bind to a hpid-containing receptor This can mean for example mat in the preparation process approximately five times more antigen is required as compared to when a hpid-containing receptor is used When a hpid-containing receptor is used, the process is considerably cheaper Parallel to reduced incoφoration, the amount of glycoside and adjuvant content per unit of antigen is increased, which partly compensates the lower amount of antigen as regards the achieved immune response, but at the same time, toxicity can increase because of the increased percentage of adjuvant The immune response, on the other hand, becomes higher in principle when using receptor-binding of the antigen, while the ongmal conformational antigemc determinants are retained Another advantage presents itself when it is desirable to join a transport (targeting) molecule and a passenger antigen to iscom or matnx If iscom or matnx has been made with hpid-containing receptors, there is more room for integrating passenger antigens in the iscom or for coupling it chemically to the matnx By using hpid-containing receptor, the binding of the passenger antigen is not influenced It becomes easier to reach optimal conditions Control of the amount of passenger antigen or transport (targeting) molecules. integrated in iscom or linked chemically to iscom or matnx, is made better If iscom is made with both a transport (targeting) molecule and an antigen using the same methods. thev mav compete for the binding regions and it is not possible to fullv control the rncoφorations of the two antigens Especially in regard to the cholera antigen CTB, which has five binding subunit, it is possible to bind up to 13 times the weight amount of the GM1 receptor There are still binding sites left in CTB, which can bind to cell receptors in the mucosa and serve as transport (targeting) molecules The weight ratio of sterol, second hpid, protein and glycoside is 0 2- 10 0 2- 10 0 2-10 1 - 100, preferably 1 1 1 5-10 to be used with subcutaneous admimstration With oral or lntranasal admimstration, the amount of glycoside can be higher in the ratio above, namely 1 -200, preferably 5-20 These amounts apply both when first making matnx and then when chemically coupling the antigens and when making iscom particles The procedure for preparing CTB (or LTB) iscoms entails mixing Quϋ A or Quil A components with a hpid mix containing cholesterol, phosphatidyl cho n and Gal 1 - 3, Gal NAcb 1 - 4 (Neu Aca2-3), gal(GMl ), which is a specific receptor for the cholera toxin (CT) and the heat-labile toxin from enterotoxic E coh (LT) as well as their subunits CTB and LTB Phosphatidylchohn (PC) can wholly or partly be replaced with phosphatidylethanolamine (PE), whereby the amino group on PE constitutes a coupling group for antigen or other desired components Unlike cholesterol, PC and PE are not essential to the iscom composition but can be replaced with other "soft" hpids Iscom or iscom matnx can be made in compositions containing a solubihzing agent such as water or physiological sahne For solubihzing agent, the composition can also include the detergent that the complex is made with if it is acceptable to human or veterinary medicine The compositions can also include other additives and fillers acceptable to human or veterinary medicine Such a composition can contain for example iscom complex and a filler such as physiological sahne It can also be composed of matnces mixed with antigen The vaccine can be made available in admimstrative forms that contain an entity with matnx in a composition containing a filler and a unit with the antigen in a composition containing a filier Both of these compositions are then intended to be administered on the same occasion The amount of iscom. matnx and antigen is chosen so that it will be pharmaceutically effective and can be decided by the expert For humans, at least 1 μg, preferably 1 - 200 μg of the antigens, should be used, whereby economic opinion sets the upper limit For animals, the dosage can be at least 0 1 μg of the antigens, depending on the antigen and the individual's size All cited publications and the Swedish pnonty application 9600648-1 are incoφorated herewith for reference Shoπ descnption of the figures Fig 1 shows that free rCTB (recombinant CTB) analyzed in a 10 to 50 % sucrose gradient after ultracentπfugation is located at the top on the gradient, te fraction 12-14 Cf Fig 2 and 3 Fig 2 shows iscoms with rCTB in a diagram where fractions in a 10 - 50 % sucrose gradient after centπfugation are plotted against 1 ) the absorbency at 595 nm for determination of the rCTB concentration using the method Bradford , and 2) CPM from analysis of 3 H cholesterol, an iscom-matnx component Iscom matnx with rCTB and GM1 at the weight ratio 13 1 is made according to example 1 and is then ultracentnfuged Iscoms with rCTB are found in the fractions 6 - 9 Nearly all rCTB are to be found in iscoms Fig 3 shows a diagram of the same kmd as Figure 2 In making iscoms in this tπal, the rCTB concentration was 100 times greater than the GM1 concentration w/w Non- incoφorated rCTB are to be found in the upper Bradford top, that is, higher up in the gradient in the fractions 10 - 12 Figs 4 A and 4B are bar graphs that show the ELISA titer in serum from mice after immunization with free rCTB and rCTB that has been incoφorated in iscom matnx The solid bars refer to subcutaneous immunization while the diagonal bars refer to lntranasal immunization Figure 4A shows serum antibody titers 5 weeks after the first immumzation while Figure 4B shows the titer 6 weeks after the second immunization The interval between the immunizations was 6 weeks Figures 5 A and 5B are bar graphs of the same kind as Figures 4 A and 4B Mice were immunized subcutaneously with 2 μg rCTB (solid bar) or lntranasallv with 4 μg rCTB (diagonal bar) Fig 5A shows serum antibodv titers 5 weeks after the first immunization while fig 5B shows the titer 6 weeks after the second immunization The interval between the immunizations was 6 weeks Fig 6 shows the antibody titers after different immunizations rCTB mixed with matnx and rCTB bound in iscom evoke, after subcutaneous immumzation, serum antibodies of subclass IgG2a and IgGl unlike rCTB, which almost only evokes IgGl Fig 6A shows the result 14 days after the first booster immunization on dav 42 while Fig 6B shows the values 4 days after the second booster immumzation on day 1 10 Fig 7 shows the result after subcutaneous immumzation of mice with rCTB bound to matnx, rCTB mixed with matnx, and only rCTB The serum antibody response 14 days after the first immumzation and 14 days after the second immumzation are shown The interval between the immunizations was 42 days Figure 8 shows the memory cell response after the second booster on day 180 for the same immumzation as in Figure 6 Four days after the booster dose, serum samples for antibody determination were taken The invention will now be descnbed more closely regarding the following procedure examples EXAMPLE 1 Incoφorating GM1 and rCTB in iscoms The cholera toxin (CT) is an effective adjuvant especially in local mucosal immumzation Even the cholera toxin's B subunit (CTB) is classified as an adjuvant because of its target- seeking qualities in local immunization, but this activity is thus limited to a guiding function for the antigen to the lymphatic cells of the intestines If CTB is bound to iscom matnx or is incoφorated in iscom. a formulation that enhances the immune response is obtained, and is effective in local and parenteral immunizations This effect is interesting in connection with vaccines against cholera and in choosing adjuvant for the other antigens for local mucosal or parenteral immunizations The recombinant cholera toxin, subunit B (rCTB) (EP 0 368 819) is mixed with different preparations with MEGA- 10 (Bachem PI 000 Decanoyl-n-methylglucamide), 20 weιght-% in H 2 0, Phosphatidylcholin (PC) (Sigma P 5763), 10 mg/ml dissolved in 20 weιght-% MEGA- 10 ιn H,0. Cholesterol (C) (Sigma C 8667), 10 mg/ml dissolved in 20 weιght-% MEGA-10 in HO, GM1 (Sigma G7641), 10 mg ml dissolved in 20 weιght-% MEGA- 10 in H,O, Phosphatidylethanolamine (PE) (Sigma P2768), 10 mg/ml dissolved in 20 weιght-% MEGA-10 ιn H 3 O, Quil A (Spikoside. Iscotec, Lulea), 100 mg/ml in H 2 0, rCTB. 5 mg/ml in a buffer solution with 0 05 M TRIS (pH 7 5), 0 2 M NaCl 0 0001 M Na2 EDTA, 0003 M NaN3 Phosphatidylcholin was mixed with cholesterol plus trace amounts of radioactive cholesterol ( 3 H-choiesterol Amersham) in the proportion 1 1 (100 mg av each lipid in 10 ml 20% MEGA- 10) and with varying amounts of GM1 from 1 μg to 7 5 μg ( 1 μg 1 7 μg, 2 5 μg, 4 μg, 5 μg, 7 5 μg) in 1 0 ml PBS (phosphate-buffered physiological NaCl- solution), pH 7 2 Into 1 ml of the six different vanants of phosphatidylcholin cholesterol-GMl - solution, Quil A was added, to a final concentration of 0 2% The mixtures were sonicated in a Sonorex TK 52 2 x 15 mm and were left at room temperature (RT) for 1 hour Then the mixtures were dialyzed against PBS, first for twenty-four hours in RT and then for twenty- four hours in a cold-room (+4 C) That matnx was formed could be seen by electron microscopy Into each of the six different matnx vanants, which differed regarding GM1 content, 100 μg rCTB were added The mixtures were left for two hours in RT The matnx particles with associated rCTB, te iscom, were purified by centnfugation in a 10 - 50% sucrose gradient in PBS for 18 hours in a TST 41 14-rotor (Kontron) at 39 000 φ in 10 C The gradient was collected in 16 to 18 fractions The fractions were analyzed in reference to rCTB using the protein-determination method according to Bradford (Bradford. Analvt Biochem , 72 ^ 1976. 248-254) and was determined choloπmetncally at 595 nm. and in reference to pids through detection of H-cholesterol. and electron microscopy to study the presence of possible matrix or iscom structures Fig 1 shows free fractions 12-14 Figs 2 and 3 show the hpid (■ ) and rCTB (D) amounts in the fractions when the ratio of rCTB GM1 is 13 1 (Fig 2), where iscom with rCTB exists in the fractions 6-9, or 100 1 (Fig 3), where non-incoφorated rCTB hes higher up in the gradient, te the fractions 10- 12 Result The greatest relative amount (weight) of rCTB that was completely incoφorated in the GM 1 matnx, te the iscom, was 13 times higher than the amount of GM1 (Fig 2) In several other expenments, we have seen the same ratio If a higher amount of rCTB is added, the suφlus rCTB is found higher up on the gradient unassociated with 3 H cholesterol, which shows that this rCTB is not incoφorated If a smaller amount of rCTB is added, aggregates are formed through cross-linking because rCTB has five possible binding sites to GM1 Matnx with associated rCTB, te iscom, is to be found in the fractions 6 - 9 (Fig 2) Similar results are achieved with phosphatidylethanol-amine in matnx or iscom instead of phosphatidylcholin (results not presented) Conclusion rCTB can effectively be bound to matnx that contains the glycohpid GM 1 An addition of an appropnate amount of GM 1 dunng the matnx preparation implies an efficient procedure method EXAMPLE 2 In this example, it is shown that rCTB incoφorated in iscom evokes a higher antibody response than free rCTB GM 1 matnx was prepared in the same way as in example 1 Phosphatidylcholin/ cholesterol and GM1 (PC/C/GM1 and Quil A) in the proportion of 1 1 0 25 5 was mixed with MEGA- 10 (final concentration 2%) The mixture was dialyzed in the same way as in example 1 rCTB was added in an amount (weight) that was 13 times higher than the amount of GM1 In the same way as in example 1, formed complex was analyzed with EM and sucrose gradient centrifugation Gradient fractions were analyzed as in example 1 regarding cholesterol and protein (rCTB) Iscoms with incoφorated rCTB were thereafter saved for use in immunization expenments Six groups of eight mice each were immunized subcutaneously with 2 g rCTB or with 4 g rCTB lntranasally on two occasions within a six week interval (see Figs 4A and 4B) rCTB was present either in a free form, te mixed wim matnx without GM 1. or bounded to matnx via GM1 Two vanants of GM1 matnx according to the above were used in the weight proportion 13 1 or 25 1 (rCTB GM1 depending on weight), ie saturated or overly saturated in regards to the proportion rCTB/GM 1 Group A Free rCTB, 2 μg rCTB rnj s c 0 μg Quil A Group B Free rCTB, 4 μg rCTB inj l n 0 μg Quil A Group C Iscom, 2 μg rCTB ( 13 x GM1 ) rnj s c 3 μg Quil A Group D Iscom. 4 μg rCTB ( 13 x GM1 ) rnj l n 6 1 μg Quil A Group E Iscom, 2 μg rCTB (25 x GM1 ) inj l n 1 6 μg Quil A Group F Iscom. 4 μg rCTB (25 x GM1 ) inj l n 3 2 μg Quil A The antibody titers in serum were measured using ELISA at different times according to In the ELISA test, the ELISA plates (Nunc, Roskdde, Denmark) were incubated with a 50 mM carbonate buffer, pH 9 5. containing 2 μg rCTB/ml Serum samples from the mice were diluted in senes The ELISA plates were treated with the diluted serum solutions Bound mice antibodies were detected with peroxidase-conjugated rabbit-anti-mouse conjugate (Dakopatts) and as a substrate. TMB, H 2 0 3 (EC diagnostics, Uppsala) was used Result The results are outhned in Figs 4A and 4B, which show serum antibody titers measured in ELISA 5 weeks after the first subcutaneous and lntranasal immunizations with rCTB (A) and 6 weeks after the second immunization (B) The interval between immunizations was 6 weeks rCTB incoφorated in iscom in the proportion of 13 1 (rCTB GM1 (weight)) evoked, after two subcutaneous immunizations with 2 μg rCTB. a titer of 87 000 Iscoms with a rCTB GM 1 ratio of 25 1 evoked titers of 50 000 Coπesponding serum antibody titers for two subcutaneous immunizations with free rCTB were 8 600 After two lntranasal immunizations with rCTB in iscom ( 13 1 ) (rCTB GM1 ) serum titers of 21 000 were obtained, while 25 1 (rCTB GM1 ) evoked serum antibody titers of 33 000 Free rCTB evoked, after two lntranasal immunizations. ELISA titers in serum of 19 000 Conclusion rCTB in iscom is. after subcutaneous immunization, more immunogenic than free rCTB, but there was no significant difference after lntranasal immumzation EXAMPLE 3 In this experiment, matnx was used as adjuvant with non-rncoφorated antigen in subcutaneous and lntranasal immunization Matnx without GM1 was prepared basically as descnbed in example 1 with the only difference that GM1 was excluded The weight proportions of phosphatidylchohn/cholesterol Quillaja were 1 1 5 Lipids were dissolved in 20% MEGA Dialvsis was conducted as in example 1 Matnx was analyzed and characterized as in example 1 using EM and analytical sucrose gradient centrifugation Matnx with GM 1 was prepared as in example 1 and rCTB was incoφorated in the proportion 13 1 (rCTB GM 1 ) When GM1 was excluded from matnx, no binding of rCTB to matnx occurred Eight mice per group were immunized subcutaneously with 2 μg rCTB in iscoms or mixed with matnx as adjuvant or lntranasally with 4 μg rCTB in iscoms or mixed with matnx as adjuvant Two immunizations were earned out within a six week interval Group C Iscom, 2 μg rCTB subcutaneously, 3 μg Quil A Group D Iscom, 4 μg rCTB lntranasally, 6 1 μg Quil A Group G Matnx mixed with, 2 μg rCTB subcutaneously, 3 0 μg Quil A Group H Matnx mixed with, 4 μg rCTB lntranasally, 6 1 μg Quil A The antibody titers in serum were measured using ELISA and the titers are given as the dilution that gives the absorbence of 1 0 Results The results are summarized in Fig 5, which shows serum antibody response after immumzation with 2μg rCTB administered s c or 4 μg rCTB admmistered I n measured in ELISA 5 weeks after the first immunization (A) and 6 weeks after the second immunization (B) The interval between immunizations was 6 weeks After two subcutaneous immunizations with rCTB mixed wid matnx as adjuvant, an average titer of 91. 000 was induced, compared to 87,000 for rCTB in iscom form After two lntranasal immunizations, 54, 000 was induced for rCTB mixed with matnx, compared to 21 , 000 for rCTB in iscom Conclusion After subcutaneous immunization, the serum antibody titers induced by rCTB in iscom form were almost as high as that induced by rCTB mixed with matnx as adjuvant After lntranasal immunization, twice as high titers after immunization with rCTB mixed with matnx were induced as with rCTB in iscom form. It is interesting to note that matnx in free form has as strong an adjuvant effect on antibody response as the iscom form of rCTB In the matnx formula, twice as much Quillaja was included Above all, it is suφnsrng that matnx in free form has an adjuvant effect after local mucosal admimstration with rCTB , which in itself has an adjuvant effect in the form of targeting when immunized through mucous membranes EXAMPLE 4 One of the tasks for an adjuvant is to evoke a strong immune response that can be measured as an antibody response or as a cell-mediated immune response Another of its tasks is to evoke the desired type of immune response, which eg can be read in IgG subclasses that reflect T-helper cell response identified with cytokine production In this experiment, it is shown that rCTB in free form without adjuvant evoke a serum antibody response that is focussed to subclass IgG By mixing rCTB with matnx or by lncoφoratrng rCTB in iscom, serum antibodies are also evoked against rCTB in the subclass IgG2a, which is associated with a THl response Eight mice per group (three groups) were immunized twice subcutaneously at a 6-week interval with 2 μg rCTB without adjuvant or with 2 μg rCTB mixed with matnx or with 2 μg rCTB-iscom The serum antibody responses were measured using ELISA according to a time schedule that can be seen in Fig 6 The distnbution of serum antibodies in classes and subclasses was analyzed using ELISA by use of class and subclass-specrfic antisera (Dakopatts, Denmark) Results Free rCTB without adjuvant mainly evoked an IgGl response against rCTB while no antibodies in subclass IgG2a could be found Both rCTB-iscom and rCTB mixed with matnx evoked both IgGl and IgG2a antibodies against rCTB (Fig 6A ) 14 days after the first booster immunization, day 42 Even after a second booster on day 1 10, free rCTB without adjuvant did not evoke an IgG2 response, while iscom and rCTB mixed with matnx gave a clear IgG2 response (Fig 6B) 4 days after the 2nd booster immunization Conclusion There are differences in quality regarding the serum antibody response in rCTB in free form without adjuvant as compared to rCTB provided with matnx as adjuvant or bound to iscom Both matnx and iscom with rCTB evoke antibodies against rCTB of subclass IgG2a as well as IgGl , unlike free rCTB. which is only able to evoke IgGl -antibodies EXAMPLE 5 The effect of vaccines against infections depends not only on the direct effect that the evoked immune response has, but also on the induced memory cells that are recruited m connection with infections The memory cell function is especially important a long time after the vaccination, when the evoked immunity will have become low A strong memory cell response, that can be recruited quickly at the time of infection, is therefore desirable Eight mice per group (3 groups) were immunized twice subcutaneously at an 8-week interval with 2 μg rCTB without adjuvant, with rCTB incoφorated in iscom, or rCTB mixed with matnx The antibody response was measured using ELISA, each group was divided into two subgroups of 4 mice each A second booster immunization was executed on dav 180 and blood tests for serum were taken 4 davs later Results The results can be seen in Fig 7 After the first immunization (day 14). the highest immune responses were evoked by rCTB mixed with matnx ( 17,000) and rCTB iscom (9.000) rCTB without adjuvant induced titers of approximately 1 ,000 Two weeks after the second immunization (the interval between lrnmumzations was 42 davs). mice in all the groups had increased their serum antibody titers appreciably The highest titers were found in the matnx group (approximately 57. 000) and the iscom group (35.000), while the titers for the group that was vaccinated with rCTB without adjuvant had titers of approximately 6,000 After the third immunization (1 e the second booster) on day 180, I e 140 days after the second immumzation, the mice that were immunized with free rCTB had antibody titers of approximately 8,000, I e just about the same titers as after the second immunization Mice that were immunized with iscom or with rCTB mixed with matnx responded after the 3rd immunization on day 180 with increased serum antibody titers for matnx (approx 90,000) and iscom (approx 70,000) (Fig 8) Serum was taken 4 days after the 3rd immunization for antibody tests Conclusion The strong antibody increase in serum in mice that were reimmunized a long time after the earlier immunization ( 140 days) with rCTB iscom or with rCTB mixed with matnx shows that a strong memory response has been evoked by the previous lmmuniations rCTB without adjuvant, however, did not show any immune response that can be boostered after a long time EXAMPLE 6 rCTB was prerncubated at 20°C for 1 hour with GM1 -containing matnx in proportions that were tested in advance so that preparation (A) should saturate matnx with rCTB, and so that preparation (B) would give an supersaturation so that approx half the amount of rCTB could not bind to matnx After incubation, the matnx was punfied from unbound rCTB through centrifugation Preparations A and B were then used for peroral, lntranasal, or intrapentoneal immunization of 8 - 10-week-old C57 B1 mice Groups of 3 mice in each group were given 3 doses with a 2-week interval between the doses Each dose contained 17 μg rCTB and 26 μg Quillaja for peroral immumzation. half the dose for lntranasal. and a sixth for intrapentoneal immunization Three more groups of mice were given peroral, lntranasal, and intrapentoneal immunizations, respectively, with conesponding amounts of matnx (not containing GMl ) mixed with rCTB One week after the third dose, the animals were killed, exsanguinated, and perfused with PBS-hepaπn whereafter lung tissue was taken from both lungs and crushed, and pieces of the intestinal canal were taken from the upper, middle and lower parts of the small intestine and were crushed The tissue was frozen at -30°C and was then thawed and suspended in PBS-1% saponine ( 1 ml per 1 mg tissue) and was extracted in cold (+4° to IOC) over the night The tissue extract and sera were then titered for specific antibodies against CTB using GMl -ELISA The results can be seen in Table 1 It is evident that all of the preparations A-C give high serum antibody responses after intrapentoneal and lntranasal immunization and that lntranasal immunization with (A) and (B) stimulate good local IgA antibody titers in tissue extract from respiratory tract cells TABELL 1 ANTIBODY TITERS IN MICE IN SERUM AND TISSUE EXTRACT AFTER INTRAPERITONEAL (IP) INTRANASAL (IN) OR ORAL IMMUNIZATION WITH B-SUBUNIT (rCTB) FROM THE CHOLERA TOXIN IN ISCOM LUNG INTESTINE SERUM IgA IgG IgA IgG IgA IgG A PO <2 15 42 <2 35 1400 IN 2900 20,700 21 140 970 >400,000 IP <2 7000 18 350 <2 260,000 B PO <2 14 22 20 10 6,800 IN 1550 7000 240 510 1420 >400,000 IP <2 220 100 100 10 120,000 C PO <2 76 39 39 <2 99,000 IN 340 5,400 28 415 350 380,000 IP - 6,700 - 450 - >400,000 D PO 0 _ 30 N d - _ =CTB LN 500 - 50 N d - 30,000 E PO 20 2,100 4,300 800 1,300 87,000 =CTB+LN 10,000 46,000 500 5,100 40,000 600,000 CT IP N d 2,300 100 480 630 79,000 3 immunizations, 3 mice per group Median titers are shown Mice were immunized 3 x A= PC/C + GMl + rCTB 13 x (saturated) B= PC/C + GMl + rCTB 25x (supersaturated) C= PC/C - GMl + rCTB (PC/C and rCTB separate) D= rCTB E= rCTB + choleratoxin Dilution expressed as 1 /x is < 5 PO= peroral admimstration 20 μl ( 17 μg CTB & QA 26 μg) IP= intrapentoneal 3 μl IN= lntranasal 10 μl EXAMPLE 7 This example shows that an iscom containing matnx with GMl and to which rCTB has been bound and incoφorated together with an Ovalbumin (OVA) which has been provided with a hpid tail evokes antibody response against rCTB and against OVA after one lntranasal (IN) immunization Lipidating OVA Reagent 1 mg OVA 1 mg phosphatidylethanolamin (PE), with small amounts of 14 C-labelled PE 1 4 mg N-hydroxisulfosuccinimide 38 4 mg l-e yl-3-(3-dιmemylammopropyl)-charbodιιmιd-HC l H 2 O to a volume of 2 ml The mixture was incubated for 2 hours on a shakeboard in room temperature This OVA was incoφorated in iscoms with and without GMl, analogously with the method descnbed earher in example 1 The iscoms were characterized through electron microscopy (EM) and analytic sucrose gradient centrifugation in the same was as in example 1 In iscom preparation the following ingredients were used Lipidated OVA, 2 ml 300 μg Cholesterol 1000 μg Spikoside (Quil A) 5000 μg H2O to a volume of 2 15 ml For preparation, see example 1 When the iscoms were also to contain GMl , the following ingredients were used Lipidated OVA 300 μg Cholesterol 1000 μg GMl 50 μg Spikoside (Quil A) 5000 μg Total volume 2 2 ml (H2O) In preparing OVA-rCTB iscoms. OVA-GMl iscoms were mixed with 13 times higher amounts (weight) rCTB than GMl The amounts were calculated in the same way as in EP 180 562, example 2 1 Five groups of eight mice each were immunized lntranasally twice with a six-week interval according to the following schedule Group A OVA (free), 10 μg lntranasally Group B OVA-iscom, 10 μg antigen lntranasally Group C OVA-iscom + rCTB (free), 10 μg of each antigen lntranasally Group D OVA-rCTB iscom, 10 μg of each antigen lntranasally Group E OVA-rCTB iscom, 2 μg of each antigen subcutaneously Group F OVA free + rCTB free 10 μg of each antigen lntranasally 3 weeks after the first immumzation and 2 weeks after the second immunization, serum samples were collected Lungs were prepared 2 weeks after the first and second immunizations for extraction of IgA antibodies Antibody titers in serum and lung extract were determined in the same way as in examples 1 and 2 Results after one immunization The mice in group D responded with significant levels of antibody titers against rCTB in serum Significant antibody titers against rCTB were detected in lung extract Lower antibody titers were obtained against OVA in both serum and lung extract After subcutaneous immunization (group E) approx the same serum antibody levels against CTB as against OVA were obtained No antibody response was measured against rCTB or OVA in lung extract In the mice in group C, that had been immunized lntranasally with OVA-iscoms plus free rCTB, antibody titers against rCTB were measured with ELISA serum antibody titres that were of the same level as those in the mice in group D No antibody titers against OVA could be measured in serum In lung extract, significant titers against rCTB were measured, but no or very little antibody response could be measured against OVA In the mice in group F moderate antibody titers were obtained in serum and lung extract against rCTB after primary immunization (i n ) but not against OVA In mice in the remaining groups ( A, B) no antibody titers against OVA could be measured in serum nor in lung extract Results after the second immunization High antibody titers against OVA in serum were measured in the mice in groups D and E, te the mice that were immunized lntranasally or subcutaneously, respectively, with OVA-rCTB iscoms In lung extract from the mice in group D, antibody titers against both rCTB and OVA were measured No or very low titers were measured in lung extract in mice that were immunized subcutaneously with OVA-rCTB iscoms (group E) In the mice in group C, high antibody responses against rCTB in serum were measured, but very low serum titers were obtained against OVA In lung extract antibody titers against rCTB but not against OVA were measured In the mice in group B (OVA-iscom) low titers against OVA in both serum and lung extract were measured Free OVA (group A) evoked no detectable antibody titers. in either serum or lung extract After the second immunization several-fold serum antibody increase of titres against rCTB but not against OVA was obtained After the second immunization, IgA antibody titers against rCTB were measured in the lung that were significant but no antibody response was measured against OVA Conclusion The results show that iscoms containing rCTB as transport (targeting) molecules and OVA as passenger antigen effectively induce antibody response against both rCTB and OVA in lung extract and serum Only OVA. OVA iscoms (iscoms with only passenger antigen) or free OVA plus rCTB iscoms evoked no or very low antibody response against OVA in serum and luneextract

Claims: Patent claims 1 Lipid-containing particles, chosen from iscoms and lscom-matnx. characterized in that thev compnse one or more hydrophobic receptor-molecules for antigen substances, which receptor molecules have been integrated in the particle, and are chosen from hpid-containing receptors or receptors that are hydrophobic, and that the receptor molecules possibly are bound to target seeking and or antigenic substances 2 Lipid-contarmng particle according to claim 1 that is composed of iscoms containing at least one glycoside, at least one hpid and at least one hydrophobic protein or peptide-containmg antigen characterized by in that it compnses one hpid-containing receptor and possibly at least one antigen bound to the receptor 3 Lipid-contarmng particle according to claim 1 that is composed of iscom-matnx containing at least one glycoside and at least one hpid, characterized in that it compnses one hpid-containing receptor and possibly at least one antigen bound to the receptor 4 Lipid-containing particle according to claim 3, characterized by a content of at least two antigens or one antigen and one target-seeking molecule, and that one antigen is bound to a receptor-binding molecule 5 Lipid-containing particles accordmg to claims 1 -4, characterized by the receptor molecule being a hpid-containing receptor 6 Lipid-containing particles according to one of the claims 1 -5, characterized by the receptor molecule being the hpid-containing receptor GMl of the cholera toxin and the antigen being the cholera toxin or parts thereof, such as its B-subunit or immunologically closely related proteins such as heat-labile enterotoxin from E coli, or its subunit that binds to the receptor 7 Lipid-containing particles accordmg to one of the claims 1-5, characterized by the receptor molecule being a hydrophobic protem 8 Lipid-contarmng particles according to claim 7, characterized by the receptor molecule being a glycoprotein or fucosylated blood group antigen 9 Lipid-ccmtarning particles accordmg to claim 7, characterized by the receptor molecule being the glycoprotein that b ds to heat-labile enterotoxin from E coh or subumts thereof and by the antigen being the enterotoxin from E coh or parts thereof 10 Vaccine prφaration for prophylaxis and/or immunotherapy, characterized by a content of particles according to one of the claims 1-9

Inventors: EKSTROEM JILL, LOEVGREN BENGTSSON KARIN, MOREIN BROR, EKSTROEM, JILL, LOEVGREN BENGTSSON, KARIN, MOREIN, BROR
Applicants: EKSTROEM JILL, LOEVGREN BENGTSSON KARIN, MOREIN BROR, EKSTROEM, JILL, LOEVGREN BENGTSSON, KARIN, MOREIN, BROR
Application year: 1997
Main classification: A61K39
IPC codes: A61K9, A61K39, A61K47, A61P37